Follow
'An alternative to gene therapy is enhancing the enzymatic activity through small molecules, an approach pursued by Bial, based in Portugal, which is conducting phase 2 trials of LTI-291, an activator of glucocerebrosidase acquired from Lysosomal Therapeutics.'
@cyrilpedia
I haven't looked at Parkinson's much.
I have looked at Alzheimer's quite a bit.
The Amyloid Hypothesis is bad work, and they had to have known it was bad work for the better part of 30 years, but they kept with it because pursuing it was good for stock prices.
One can't help but wonder how frequently good money is thrown after bad to manipulate investors, to get government grants, to get approval for medications they know will never provide any real benefit.
Probably a whole bunch.